74. Cannon, C. P. et al. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. N. Engl. J. Med. 350, 1495–1504 (2004).
75. Perkins, G. D. et al. A Randomized Trial of Epinephrine in Out-of-Hospital Cardiac Arrest. N. Engl. J. Med. 379, 711–721 (2018).
76. Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G. & PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 6, e1000097 (2009).
77. Moher, D., Tetzlaff, J., Tricco, A. C., Sampson, M. & Altman, D. G. Epidemiology and Reporting Characteristics of Systematic Reviews. PLoS Med. 4, e78 (2007).
78. Shojania, K. G. et al. How Quickly Do Systematic Reviews Go Out of Date? A Survival Analysis. Ann. Intern. Med. 147, 224 (2007).
79. Health On the Net (HON): HONcode: Principles in Russian. Available at: http://www.hon.ch/HONcode/Webmasters/Russian/. (Accessed: 29th October 2018)
80. Грипп. Available at: https://www.who.int/ru/news-room/fact-sheets/detail/influenza-(seasonal). (Accessed: 25th October 2018)
81. Influenza (Flu) Antiviral Drugs and Related Information | FDA. Available at: https://www.fda.gov/drugs/information-drug-class/influenza-flu-antiviral-drugs-and-related-information. (Accessed: 29th October 2018)
82. Influenza Antiviral Medications: Summary for Clinicians. Centers for Disease Control and Prevention Available at: https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm. (Accessed: 29th October 2018)
83. What You Should Know About Flu Antiviral Drugs | CDC. Available at: https://www.cdc.gov/flu/treatment/whatyoushould.htm. (Accessed: 29th October 2018)
84. Эффективность и безопасность гепатопротекторов с точки зрения доказательной медицины. Available at: http://health-ua.com/article/15676-effektivnost-i-bezopasnost-gepatoprotektorov-s-tochki-zreniya-dokazatelnoj-. (Accessed: 29th October 2018)
85. Saito, Z. et al. Effectiveness of hepatoprotective drugs for anti-tuberculosis drug-induced hepatotoxicity: a retrospective analysis. BMC Infect. Dis. 16, 668 (2016).
86. Rambaldi, A., Jacobs, B. P. & Gluud, C. Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. Cochrane Database Syst. Rev. (2007). doi:10.1002/14651858.CD003620.pub3
87. Day, P. et al. Клинические рекомендации EASL – EASD – EASO по диагностике и лечению неалкогольной жировой болезни печени (2016).
88. Ivashkin, V. et al. Diagnostics and treatment of non-alcoholic fatty liver disease: clinical guidelines of the Russian Scientific Liver Society and the Russian gastroenterological association. Vshtspb.Ru 24–42 (2013).
89. Elia, V. et al. Permanent physico-chemical properties of extremely diluted aqueous solutions of homeopathic medicines. Homeopathy 93, 144–50 (2004).
90. Kayne, S. B. Homeopathic pharmacy : theory and practice. (Elsevier Churchill Livingstone, 2006).
91. Chakraborti, D. et al. Arsenic toxicity from homeopathic treatment. J. Toxicol. Clin. Toxicol. 41, 963–7 (2003).
92. HRI – Homeopathy use around the world. Available at: https://www.hri-research.org/resources/essentialevidence/use-of-homeopathy-across-the-world/. (Accessed: 29th October 2018)
93. Dantas, F. et al. A systematic review of the quality of homeopathic pathogenetic trials published from 1945 to 1995. Homeopathy 96, 4–16 (2007).
94. Junod, S. W. An alternative perspective: homeopathic drugs, Royal Copeland, and federal drug regulation. Food Drug Law J. 55, 161–83 (2000).
95. Воробьев П. А., Безмельницына Л. Ю., Краснова Л. С. & Холовня М. А. Оценка медицинской технологии применения лекарственных препаратов с ноотропным и психостимулирующим действием: кортексин, пирацетам, цитиколин, церебролизин. Клиническая геронтология 53–73 (2017).
96. Flicker, L. & Grimley Evans, J. Piracetam for dementia or cognitive impairment. Cochrane Database Syst. Rev. (2004). doi:10.1002/14651858.CD001011
97. Cerebrolysin | EVER Pharma. Available at: https://www.everpharma.com/portfolio/neurology/cerebrolysin/. (Accessed: 29th October 2018)
98. Vastag, B. Biotechnology: Crossing the barrier. Nature 466, 916–918 (2010).
99. Chen, N. et al. Cerebrolysin for vascular dementia. Cochrane Database Syst. Rev. (2013). doi:10.1002/14651858.CD008900.pub2
100. Ziganshina, L. E., Abakumova, T. & Vernay, L. Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst. Rev. (2017). doi:10.1002/14651858.CD007026.pub5
101. Смирнова М. Д. & Агеев Ф. Т. Статины – старые мифы и новые факты. Регулярные выпуски ‘РМЖ’ 1421–1428 (2017).
102. Chasman, D. I. et al. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 291, 2821–7 (2004).
103. Liao, J. K. Safety and efficacy of statins in Asians. Am. J. Cardiol. 99, 410–4 (2007).
104. Stroes, E. S. et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur. Heart J. 36, 1012–22 (2015).
105. Kashani, A. et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 114, 2788–97 (2006).
106. Riaz, H. et al. Meta-analysis of Placebo-Controlled Randomized Controlled Trials on the Prevalence of Statin Intolerance. Am. J. Cardiol. 120, 774–781 (2017).
107. McGuinness, B., Craig, D., Bullock, R. & Passmore, P. Statins for the prevention of dementia. Cochrane Database Syst. Rev. (2016). doi:10.1002/14651858.CD003160.pub3
108. O’Donoghue, M. et al. Lipoprotein-Associated Phospholipase A 2 and Its Association With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy – Thrombolysis In Myocardial Infarction) Trial. Circulation 113, 1745–1752 (2006).
109. Taylor, F. et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst. Rev. (2013). doi:10.1002/14651858.CD004816.pub5
110. Silva, M. A., Swanson, A. C., Gandhi, P. J. & Tataronis, G. R. Statin-related adverse events: A meta-analysis. Clin. Ther. 28, 26–35 (2006).
111. Finegold, J. A., Manisty, C. H., Goldacre, B., Barron, A. J. & Francis, D. P. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice. Eur. J. Prev. Cardiol. 21, 464–474 (2014).
